Drugs / Peg-IFNα-2b
Peg-IFNα-2b
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00871533 | Sep 2009 → Aug 2017 | melanoma | University of Pittsburgh | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03969017 | Jun 2019 → May 2022 | cirrhosis of liver | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT02227277 | Feb 2015 → Feb 2018 | AIDS | The Wistar Institute | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07071636 | Aug 2025 → Dec 2027 expected | chronic hepatitis B virus infection, metabolic dysfunction-associated steatotic liver disease | Shenzhen Third People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04254874 | Feb → Jun 2020 | COVID-19 | Tongji Hospital | Unknown | No outcome recorded |
| Phase not applicable3 trials · 1 missed | ||||||
| — | NCT06457477 | Jun 2024 → Dec 2025 | chronic hepatitis B virus infection | Beijing 302 Hospital | Unknown | No outcome recorded |
| — | NCT05490836 | Sep 2022 → Aug 2024 | chronic hepatitis B virus infection | Huashan Hospital | Unknown | No outcome recorded |
| — | NCT05451420 | Dec 2017 → Jun 2020 | chronic hepatitis B virus infection | Henan Provincial People's Hospital | Completed | Missed primary |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT04189276 Comparator | Dec 2019 → Jun 2021 | hepatitis B virus infection | Tasly Tianjin Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT07282249 Comparator | Dec 2025 → Apr 2027 expected | chronic hepatitis B virus infection | Grand Theravac Life Sciences (Nanjing) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT01718145 Comparator | Nov 2012 → Dec 2013 | hepatitis C virus infection | Bristol-Myers Squibb | Completed | No outcome recorded |
| — | NCT06357806 Comparator | May 2024 → Oct 2026 expected | chronic hepatitis B virus infection | Beijing 302 Hospital | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-11-02 | Merck Sharp & Dohme LLC | Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for Chronic Hepatitis C Virus merck.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peg IFNα-2b | “Therefore, this study aims to conduct a prospective cohort study to compare the therapeutic effects of pegylated interferon α-2b (Peg IFNα-2b) combined with nucleos(t)ide...” NCT07071636 ↗13“Participants in NAs+Peg IFN Group will be treated by Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or 90ug per week during the treatment if patients could not...” NCT03969017 ↗ “Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks” NCT04254874 ↗ “Pegylated interferon α-2b (PegIFNα-2b) therapy can help inactive hepatitis B surface antigen (HBsAg) carriers (IHCs) achieve clinical cure.” PMID 37577817 ↗ Aug 2023 |
| Known as | Interferon | “Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks” NCT04254874 ↗ |
| Known as | Peginterferon Alfa-2b | “Peginterferon Alfa-2b Combined With Tenofovir Alafenamide Improves the Functional Cure Rate in Patients With HBeAg Negative Chronic Hepatitis B” NCT05490836 ↗ |
| Known as | pegylated interferon (Peg IFN)α-2b | “pegylated interferon (Peg IFN)α-2b” NCT03969017 ↗ |
| Known as | pegylated interferon alpha 2b | “The purpose of this study is to determine if treatment with pegylated interferon alpha 2b (peg-IFN-α2b) will reduce the amount of integrated HIV DNA in peripheral blood cells...” NCT02227277 ↗ |
| Known as | pegylated interferon α-2b | “Therefore, this study aims to conduct a prospective cohort study to compare the therapeutic effects of pegylated interferon α-2b (Peg IFNα-2b) combined with nucleos(t)ide...” NCT07071636 ↗1“Pegylated interferon α-2b (PegIFNα-2b) therapy can help inactive hepatitis B surface antigen (HBsAg) carriers (IHCs) achieve clinical cure.” PMID 37577817 ↗ Aug 2023 |
| Modality | Protein / enzyme biologic | “pegylated interferon (Peg IFN)α-2b” NCT03969017 ↗ |
| Route | Subcutaneous | “SC injection at 6mcg/kg will be performed systemically” NCT00871533 ↗ |